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Low Levels of High-Density
Lipoprotein Cholesterol
Due to Lecithin:Cholesterol
Acyltransferase Mutations
Increase Carotid Atherosclerosis*
Sergio Fazio, MD, PHD, MacRae F. Linton, MD
Nashville, Tennessee
Despite the long-held knowledge of an inverse relationship
between plasma high-density lipoprotein (HDL) choles-
terol levels and rates of cardiovascular disease (CVD) in
populations, the HDL hypothesis has recently been shaken
to its foundations by a barrage of controversial data. For
example, clinical trials of an agent (torcetrapib) that in-
creases HDL cholesterol by inhibiting cholesteryl ester
transfer protein (CETP), an essential transferase that moves
cholesterol from HDL to apolipoprotein B (apo B)–
containing lipoproteins, have shown unexpected harm with
increased cardiovascular events after 1 year of treatment
among subjects who were already taking protective doses of
atorvastatin (1). In addition, coronary and carotid imaging
studies with the same agent failed to show vascular improve-
ments attributable to the drug or to the increase in HDL
cholesterol (2,3). Moreover, genetic studies have challenged
See page 2481
the role of HDL in atherogenesis by providing observations
contrary to the dogma that HDL is a protector of the artery
wall. For example, mutations in CETP or hepatic lipase (HL),
both causing significant increases in HDL cholesterol presum-
ably sustained over the lifetime of the carriers, are associated
with increased cardiovascular event rates compared with non-
carriers (4–6). It is thus particularly important that the study
y Duivenvoorden et al. (7) reported in this issue of the Journal
provides support for the previously intuitive concept that low
HDL increases the risk of CVD. In this study, 40 subjects (38
heterozygotes, 2 homozygotes) with mutations in the gene for
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with 40 controls (both family members and unrelated individ-
uals) matched for age and cardiovascular risk factors. Subjects
and controls were, on average, 42 years old, borderline over-
weight, nonsmokers, and moderate alcohol users. One-half of
the carriers were taking lipid-lowering drugs (mostly statins)
compared with only 1 user among the controls. The lipid panel
showed no differences between groups in total cholesterol,
low-density lipoprotein (LDL) cholesterol, and apo B levels.
As expected, carriers had much lower HDL cholesterol and
apolipoprotein A-I (apo A-I) levels compared with controls
(34 mg/dl vs. 54 mg/dl and 119 mg/dl vs. 150 mg/dl,
respectively), attributable to a 28% reduction in plasma LCAT
activity. The absence of differences in LDL cholesterol levels
goes along with the phenotype of incomplete LCAT defi-
ciency, in which only the transferase activity linked to HDL is
defective (fish eye disease). In cases of complete LCAT
deficiency (familial LCAT deficiency), the transferase activity
associated with LDL is also lost, and, as a consequence, LDL
levels are reduced (8).
In this study, the outcome measure was carotid wall
thickness, and the evaluation was based on 2 imaging
modalities: 3.0-T carotid magnetic resonance imaging
(MRI) and classic B-mode ultrasound. Both MRI and
B-mode ultrasound data imaging were analyzed by blinded
operators. The results are compatible with a negative effect
of the genetically determined low HDL on carotid artery
wall thickening. The carriers had a 10% higher normalized
wall index (primary outcome) and a 20% higher mean wall
area and total wall volume (secondary outcomes). In addi-
tion, exploratory endpoints for the MRI analyses showed
that 50% of the carriers and 8% of controls had atheroscle-
rotic plaque components defined as either lipid-rich tissue
or calcified material. There was also a significant difference
in total plaque volume (102 mm3 vs. 3 mm3 in carriers vs.
noncarriers, respectively). All these differences were signif-
icant after adjustment for the major risk factors including
age, sex, blood pressure, body mass index, LDL cholesterol,
smoking, and family history of CVD. Interestingly, the
measurement with B-mode US (for common carotid
intima-media thickness [CCIMT]) showed a trend for an
increase in carriers versus controls of 12.5% (0.72 mm vs.
0.64 mm), but this difference did not come close to
statistical significance (p  0.14) even though it was similar
in size to the difference between groups in the MRI study.
The knowledge that genetically determined low HDL
cholesterol levels are associated with increased development of
carotid plaques provides a ray of light for investigators and
enterprises hard at work identifying a valid therapeutic target to
increase plasma HDL cholesterol or, better yet, to improve
reverse cholesterol transport (RCT). However, these newest
data are far from being unchallenged and do not definitely put
the case to rest. Similar studies have been done in the past with
carriers of dysfunctional LCAT mutants or by evaluating
LCAT activity as a predictor of CVD in populations or as
doi:10.1016/j.jacc.2010.11.091associated parameters in patients with CVD. Two previous
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among carriers of LCAT mutations provided opposite results.
One study, from the laboratory that also conducted the current
study, found an increased CCIMT among Dutch carriers of
LCAT mutations causing fish eye disease compared with
controls (9). Another study by Calabresi et al. (10) found that
talian carriers of LCAT mutations causing familial LCAT
eficiency had a significantly decreased CCIMT. This puts
nto question 2 issues: 1) the value of other lipid parameters in
etermining the atherogenicity of HDL reduction due to
CAT mutations and 2) the sensitivity of B-mode ultrasound.
n fact, in the study by Calabresi et al. (10), the carriers of
CAT mutations had lower LDL levels than controls because
f the absence of functional LCAT on apo B–containing
ipoproteins. This suggests that sustained low LDL cholesterol
evels prevail over sustained low HDL cholesterol levels in
redicting vascular changes, even in subjects whose exclusive
ipid abnormality is low HDL cholesterol. This would certainly
e in line with the current view of LDL as primary target of
ipid therapy for CVD risk reduction. It is also possible that the
ivergent results of the 2 studies are explained by inherent
echnical limitations of B-mode ultrasound. This possibility is
upported by the fact that in the current study, B-mode
ltrasound was not able to demonstrate a significant effect of
CAT mutations and lifetime low HDL on CCIMT. Had
his been another ultrasound-only study, it would have only
dded to the confusion. This is a strong reminder that more
dvanced imaging approaches are necessary to delineate the
ole of single gene contributors to a complex disease such as
re-clinical atherosclerosis.
Population and clinical studies, by and large, have elimi-
ated a major role for variations in LCAT activity or mass as
redictors of CVD (11,12). In the experimental world, results
ave been equally uninformative and confusing. Deletion of
CAT in mice has been linked to both increased and de-
reased atherosclerosis, depending on the levels of apo B–con-
aining lipoproteins (13). Overexpression of LCAT in trans-
enic mice produced an expected increase in HDL cholesterol
nd an unexpected impairment in RCT (41% reduction in the
eturn of HDL cholesterol to the liver) with paradoxically
ncreased atherosclerotic plaque volume (14). It has to be noted
that the mouse does not have CETP activity in plasma and
that its HL is mostly circulating rather than liver bound. When
LCAT was overexpressed in rabbits, which, like humans,
express CETP and have liver-bound HL, the increased HDL
cholesterol was linked with significant reduction in atheroscle-
rotic burden. Of note, when CETP was coexpressed in LCAT
transgenic mice, the negative vascular effects were deleted, and
the phenotype reverted to show reduction in atherosclerosis
(15). These data make it clear that therapeutic exploitation of
the RCT must be carefully orchestrated in consideration of
diverging results that may be collected depending on the status
of different components of the system. For example, activation
of LCAT under conditions of inhibited CETP (with niacin
therapy at present, CETP inhibitors maybe in the future)
(16,17) may produce altered plasma cholesterol flux with
vultimately negative effects on vascular health. This notwith-
standing, it is encouraging to see an important regulator of
RCT confirming the dangers of low HDL cholesterol levels
and consolidating its position as a valid therapeutic target. In
this regard, it is worth noting that 2 groups have recently
reported work on the use of recombinant LCAT in experi-
mental animals. One group has studied the effect of injecting
recombinant LCAT in primates and showed significant im-
provement in plasma LDL and HDL levels (18). Closer to the
therapeutic level, another group has recently reported the
production of a hyperfunctional engineered LCAT (about
7-fold more active than normal human LCAT) that increased
HDL cholesterol 3-fold and reduced cholesterol accumulation
in aortic plaques after infusion in rabbits (19).
The contribution of HDL to RCT can be separated into 2
stages: 1) the stage of cholesterol acquisition from peripheral
tissues, which requires the presence of abundant amounts of
the cholesterol acceptor apo A-I in the form of pre-beta HDL
particles, the up-regulation of cellular lipid transporters such as
ABCA1 and ABCG1 to facilitate export of intracellular
cholesterol to HDL, and the activity of LCAT, which effi-
ciently esterifies cellular free cholesterol to promote particle
maturation via expansion of the HDL core; and 2) the stage of
cholesterol delivery, which involves CETP action to transfer
cholesterol to apo B–containing lipoproteins in exchange for
triglycerides, remodeling of the HDL particle by action of HL,
and interaction between apo A-I and the HDL receptor
SR-BI to deliver HDL’s cholesterol cargo to liver cells.
Therapeutic HDL cholesterol increases can be accom-
plished by facilitating one of the steps of stage 1 or by
inhibiting one of the steps of stage 2. Despite the negative
results seen with the first CETP inhibitor, active investigation
is in place with newer molecules, 2 of which apparently lack
toxic off-target effects (20,21). Some emphasis is also being
placed on inhibitors of SR-BI, even though mouse data suggest
that the increase in HDL caused by the loss of SR-BI may not
be protective (22). A safer avenue of intervention, at least on
theoretical grounds, is offered by interventions improving the
efficiency of the steps involved in stage 1, aiding cholesterol exit
from peripheral cells, and HDL formation and maturation.
Multiple approaches are being used to achieve this goal,
including small molecules activating apo A-I production,
infusion of small recombinant HDL, and reinfusion of delipi-
dated HDL (pre-beta particles) (23). The study by Duiven-
voorden et al. (7) provides much needed support for the idea
that activation of LCAT may be exploited as a way to increase
HDL cholesterol levels, improve RCT, and enhance vascular
homeostasis.
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